Key Takeaways LLY stock crossed its 50-day SMA, signaling potential bullish momentum after recent underperformance. Mounjaro and Zepbound drove about 48% of Q1 revenues, aided by global launches and supply gains. LLY expects 2025 revenues of $58B-$61B, with growth fueled by Mounjaro, Zepbound and other new drug approvals.Eli Lilly and Company (LLY) has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through i ...